Form 4: Telesis Bio Inc. Director Annette Tumolo Reports Stock and Option Grants
SEC Form 4 Filing
Annette Tumolo, a director at Telesis Bio Inc., reports the acquisition of restricted stock units and stock options.
Summary
- Annette Tumolo, a director at Telesis Bio Inc., filed a Form 4 detailing changes in beneficial ownership.
- On July 6, 2023, Tumolo acquired 46,752 shares of common stock through restricted stock units (RSUs) and disposed of 121,363 shares, also acquiring options to buy 70,129 shares at $1.54.
- On May 1, 2024, Tumolo acquired 36,406 shares of common stock through RSUs and options to buy 30,362 shares at $0.3557.
- The RSUs vest based on continued service, either on the one-year anniversary of the grant date or the date of the annual meeting of the Issuer's stockholders following the date of grant.
- Some RSUs granted on May 1, 2024, will vest on January 1, 2025, while others vest on the earlier of the one-year anniversary of the grant date or the date of the annual meeting of the Issuer's stockholders following the date of grant.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of stock and option grants to a director. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information.
Positives
- The grants of RSUs and stock options to a director may align her interests with those of the shareholders.
Future Outlook
The vesting of RSUs and stock options is contingent upon the Reporting Person's continued service as a Service Provider, as defined in the Issuer's 2021 Stock Incentive Plan.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders, such as directors and officers, in their company's stock.
Stakeholder Impact
- The grants of RSUs and stock options to a director may align her interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 07/06/2023 | Acquisition of 46,752 shares via RSUs, disposal of 121,363 shares, and acquisition of options to buy 70,129 shares at $1.54. |
| 05/01/2024 | Acquisition of 36,406 shares via RSUs and options to buy 30,362 shares at $0.3557. |
| 01/01/2025 | Vesting date for 16,165 RSUs granted on May 1, 2024, contingent on continued service. |
| 05/03/2024 | Date of signature by Attorney-in-Fact, Rob Cutler. |
Keywords
Form 4, beneficial ownership, Telesis Bio Inc., TBIO, Annette Tumolo, restricted stock units, stock options, director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.